Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma

References

• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372:311–319.
   PubMed Web of Science ®Google Scholar
• Younes A, SA, Shipp M, Zinzani PL, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283–1294.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Human medicines; [cited 2017 Sept 29]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003985/human_med_001876.jsp&mid=WC0b01ac058001d124.
   Google Scholar
• Food and Drug Administration. Hematology/Oncology (Cancer) Approvals & Safety Notifications; [cited 2017 Sept 29]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm.
   Google Scholar
• Delbecq AL, vdVA, Gustafson DH. Group techniques for program planning: a guide to nominal group and Delphi processes. Glenview (IL): Scott, Foresman and Co; 1975.
   Google Scholar
• Williams PL, Webb C. The Delphi technique: a methodological discussion. J Adv Nurs. 1994;19:180–186.
   PubMed Web of Science ®Google Scholar
• Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28:368–376.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492–2502.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–3068.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016;128:2489–2496.
   PubMed Web of Science ®Google Scholar
• Roemer MGM, Redd RA, Cader FZ, et al. Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma. J Clin Oncol. 2018;36(10):942–950.
   PubMed Web of Science ®Google Scholar
• Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35:2125–2132.
   PubMed Web of Science ®Google Scholar
• Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34:2690–2697.
   PubMed Web of Science ®Google Scholar
• Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34:3733–3739.
   PubMed Web of Science ®Google Scholar
• Pembrolizumab approved for Hodgkin lymphoma. Cancer Discov. 2017;7:OF1.
   Web of Science ®Google Scholar
• Bristol-Myers Squibb. Opdivo (nivolumab) package insert; [cited 2018 Feb 05]. Available from: https://packageinserts.bms.com/pi/pi_opdivo.pdf.
   Google Scholar
• Food and Drug Administration. Nivolumab (Opdivo) for Hodgkin lymphoma; [cited 2016; May 17]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501412.htm.
   Google Scholar
• Merryman RW, Kim HT, Zinzani PL, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017;129:1380–1388.
   PubMed Web of Science ®Google Scholar
• Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase ii CheckMate 205 trial. J Clin Oncol. 2018;36:1428–1439.
   PubMed Web of Science ®Google Scholar
• Herbaux C, Merryman R, Devine S, et al. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood. 2018;132:9–16.
   PubMed Web of Science ®Google Scholar
• Angenendt L, Schliemann C, Lutz M, et al. Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:443–445.
   PubMed Web of Science ®Google Scholar
• Yared JA, Hardy N, Singh Z, et al. Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:850–852.
   PubMed Web of Science ®Google Scholar
• Shad AT, Huo JS, Darcy C, et al. Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: a case report. Pediatr Blood Cancer. 2017;64:e26257.
   Web of Science ®Google Scholar
• Villasboas JC, Ansell SM, Witzig TE. Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective. Oncotarget. 2016;7:13260–13264.
   PubMed Web of Science ®Google Scholar
• Aslan A, Aras T, Ozdemir E. Successful treatment of relapsed/refractory Hodgkins lymphoma with nivolumab in a heavily pretreated patient with progressive disease after both autologous and allogeneic stem cell transplantation. Leuk Lymphoma. 2017;58:754–755.
   PubMed Web of Science ®Google Scholar
• Singh AK, Porrata LF, Aljitawi O, et al. Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma. Bone Marrow Transplant. 2016;51:1268–1270.
   PubMed Web of Science ®Google Scholar
• McDuffee E, Aue G, Cook L, et al. Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52:759–761.
   PubMed Web of Science ®Google Scholar
• Onizuka M, Kojima M, Matsui K, et al. Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Int J Hematol. 2017;106:141–145.
   PubMed Web of Science ®Google Scholar
• Godfrey J, Bishop MR, Syed S, et al. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation. J Immunother Cancer. 2017;5:11.
   PubMed Web of Science ®Google Scholar
• El Cheikh J, Massoud R, Abudalle I, et al. Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant. 2017;52:1074–1077.
   PubMed Web of Science ®Google Scholar
• Covut F, Pinto R, Cooper BW, et al. Nivolumab before and after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2017;52:1054–1056.
   PubMedGoogle Scholar
• Schoch L, BI, Fuchs E, et al. Checkpoint inhibitor therapy and graft versus host disease in allogeneic bone marrow transplant recipients of haploidentical and matched products with post-transplant cyclophosphamide [abstract]. Blood. 2017;128:Abstract 4571.
   Web of Science ®Google Scholar
• Herbaux C, Gauthier J, Brice P, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017;129:2471–2478.
   PubMed Web of Science ®Google Scholar
• Haverkos BM, Abbott D, Hamadani M, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017;130:221–228.
   PubMed Web of Science ®Google Scholar
• Sachpekidis C, Larribere L, Pan L, et al. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur J Nucl Med Mol Imaging. 2015;42:386–396.
   PubMed Web of Science ®Google Scholar
• Kwak JJ, Tirumani SH, Van den Abbeele AD, et al. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics. 2015;35:424–437.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013;19:5300–5309.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–7420.
   PubMed Web of Science ®Google Scholar
• Thompson ED, Zahurak M, Murphy A, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2017;66:794–801.
   PubMed Web of Science ®Google Scholar
• Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33:3541–3543.
   PubMed Web of Science ®Google Scholar
• Wilkerson J, Abdallah K, Hugh-Jones C, et al. Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. Lancet Oncol. 2017;18:143–154.
   PubMed Web of Science ®Google Scholar
• Dercle L, Seban RD, Lazarovici J, et al. (18)F-FDG PET and CT-scan detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti-PD1 immune checkpoint inhibitor. J Nucl Med. 2018;59(1):15–24.
   PubMed Web of Science ®Google Scholar
• Chou T, Nagai H, Kinoshita G, et al. Nivolumab in patients (Pts) with relapsed or refractory classical Hodgkin lymphoma (R/R cHL): clinical outcomes from extended follow-up of a Phase 1 Study (CA209-039). Blood. 2015;15:e162–e583.
   Google Scholar
• Cohen JB, Engert A, Ansell SM, et al. Nivolumab treatment beyond investigator-assessed progression: outcomes in patients with relapsed/refractory classical Hodgkin lymphoma from the phase 2 CheckMate 205 study. Blood. 2017;130(1):650.
   Google Scholar
• Rossi C, Gilhodes J, Maerevoet M, et al. Efficacy of chemotherapy or chemo-anti-PD-1 combination after unsatisfactory response of anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: a retrospective series from Lysa Centers. Blood. 2017;130(1):652.
   Google Scholar
• Mikhailova N, Lepik K, Kondakova E, et al. Regaining the tumor control in relapsed/refractory Hodgkin lymphoma after nivolumab failure with addition of another antineoplastic agent. Blood. 2017;130(1):1521.
   Google Scholar
• Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19:3462–3473.
   PubMed Web of Science ®Google Scholar
• Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268–3277.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–1755.
   PubMed Web of Science ®Google Scholar
• Jelinek T, Mihalyova J, Kascak M, et al. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. Immunology. 2017;152:357–371.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714–1768.
   Google Scholar
• Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131:1183–1194.
   PubMed Web of Science ®Google Scholar
• Carey CD, Gusenleitner D, Lipschitz M, et al. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017;130:2420–2430.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency. Opdivo summary of product characteristics; [cited 2018 Feb 05]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003985/WC500189765.pdf.
   Google Scholar
• European Medicine Agency. Keytruda summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003820/WC500190990.pdf.
   Google Scholar